---
title: Advances, Risks, And Implementation Challenges of Artificial Intelligence as A Force Multiplier
  for Clinical Decision Making and Health System Efficiency
url: https://doi.org/10.56201/ijmepr.v9.no7.2025.pg165.185
category: ai-marketing
subcategory: empirical
date: 2026-09
venue: INTERNATIONAL JOURNAL OF MEDICAL EVALUATION AND PHYSICAL REPORT
authors:
- Lucky Ilodigwe
source: openalex-oa
pdf_url: https://iiardjournals.org/get/IJMEPR/VOL. 9 NO. 7 2025/Advances, Risks, and Implementation 165-185.pdf
pages: 21
chars: 75715
fetched_at: '2026-11-08T19:58:15+00:00'
kb_version: 1
---

# Advances, Risks, And Implementation Challenges of Artificial Intelligence as A Force Multiplier for Clinical Decision Making and Health System Efficiency

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 165

Advances, Risks, And Implementation Challenges of Artificial
Intelligence as A Force Multiplier for Clinical Decision Making and
Health System Efficiency

Lucky Ilodigwe1, Abimbola Caleb Adesemoye2
1 Boston Consulting Group (BCG),
Austin, USA; luckyilodigwee@gmail.com
2 16 Brigade Medical Center, Nigerian Army,
Yenagoa, Nigeria; tsemoye.bimbo@gmail.com
Corresponding Author; luckyilodigwee@gmail.com
DOI: 10.56201/ijmepr.v9.no7.2025.pg165.185

Abstract
Artificial intelligence has moved from a research promise to a clinical reality, functioning less as
a replacement for practitioners than as a force mu ltiplier that extends the reach, speed, and
consistency of expert judgment across the care continuum. This review synthesizes the state of the
field as of 2025, organizing the evidence around three connected questions: what artificial
intelligence now does well in clinical decision making and operations, where its risks concentrate,
and why implementation remains the binding constraint on realized value. It traces the conceptual
evolution of the field from rule-based expert systems through statistical machine learning and deep
learning to the foundation models and large language models that now dominate attention.
Diagnostic and predictive applications have matured fastest, with imaging triage, early -warning
models for deterioration and sepsis, and medicatio n safety tools demonstrating strong
discriminative performance and, in a growing number of cases, prospective and randomized
evidence. Efficiency applications, most visibly ambient documentation systems, have produced
some of the most consistent real-world gains, reducing documentation time and clinician burnout
at scale. Against these advances sit persistent risks: algorithmic bias that can widen rather than
narrow disparities, brittleness under distribution shift, automation bias and alert fatigue at the
human interface, opacity that complicates accountability, unresolved questions of medicolegal
liability, and privacy and cybersecurity exposure. Reporting and evaluation standards specific to
artificial intelligence have emerged to raise the evidentiary ba r, and the regulatory environment
has responded with lifecycle -oriented frameworks, predetermined change control plans, and
transparency expectations, yet a durable gap remains between marketing authorization and
demonstrated clinical benefit. The central argument is that the value of clinical artificial
intelligence is determined less by model accuracy in isolation than by the quality of the
sociotechnical system into which a model is placed: governance, workflow integration,
monitoring, and the preservati on of meaningful human oversight. The review closes with a
practical agenda for closing the gap between capability and dependable, equitable benefit.

Keywords: artificial intelligence; clinical decision support; machine learning; large language
models; health system efficiency; algorithmic bias; implementation science; regulatory oversight

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 166
1. Introduction
The phrase force multiplier is borrowed deliberately. In its original usage it describes a capability
that increases the effectiveness of an existing force without increasing its size. Applied to health
systems, it captures the most defensible framing of contemporary artificial intelligence: not a
substitute for clinical expertise but an amplifier of it, allowing a finite and increasingly strai ned
workforce to see more, decide faster, and act more consistently. This framing matters because it
sets the correct evaluative standard. The question is rarely whether an algorithm can outperform a
clinician on a narrow benchmark; it is whether the clinician plus the algorithm, embedded in a real
workflow, produces better and more equitable care than the clinician alone.
Two structural pressures have made this framing urgent rather than aspirational. The first is
demand. Aging populations, the accumulation of chronic disease, and widening gaps between the
supply of clinicians and the volume of care needed have created a persistent mismatch that cannot
be closed by training alone. The second is administrative load. A substantial share of clinician time
is spent not on patients but on documentation, data retrieval, and coordination, and this burden is
a leading driver of burnout and attrition. Artificial intelligence has found its firmest early footholds
precisely at these two pressure points: sharpening deci sions where expertise is scarce, and
removing friction where routine work consumes expert time.
The maturity of the underlying technology has advanced in parallel. Regulatory authorization of
artificial intelligence and machine learning enabled medical devices has grown from a handful of
products in the middle of the last decade to well over a thousand cleared for marketing in the
United States by 2025, the large majority of them decision -support tools that flag findings for
clinician review rather than aut onomous diagnosticians (Berkley Lifesciences, 2025; Bipartisan
Policy Center, 2025). The composition of that portfolio is itself informative: it is dominated by
diagnostic imaging and cardiovascular applications, reflecting where structured data, clear ground
truth, and measurable performance have allowed models to mature first. The broader arc of the
field, from narrow task-specific tools toward the convergence of human and machine intelligence,
has been described as the emergence of a high-performance medicine in which the pairing, rather
than either party alone, defines the frontier (Topol, 2019; Rajpurkar et al., 2022).
Yet authorization is not the same as benefit. A recurring finding across the literature is that
regulatory clearance frequently rests on  retrospective performance rather than prospective
evidence of improved outcomes, and that transparency about training data, subgroup performance,
and validation remains uneven (Chouffani El Fassi et al., 2024; Muralidharan et al., 2024). The
distance between a model that performs well in a development dataset and a tool that dependably
improves care in a specific institution is the central practical problem of the field, and it is a
problem of implementation as much as of algorithms.
This review is organiz ed to reflect that reality. It surveys the advances that justify current
enthusiasm, examines the risks that temper it, and treats implementation not as an afterthought but
as the domain where value is won or lost. The scope is deliberately broad across the two functions
named in the title, clinical decision making and health system efficiency, because the most
important lesson of the past several years is that these functions are inseparable: a decision-support
tool that adds cognitive burden fails even if it is accurate, and an efficiency tool that quietly shapes
clinical content is a decision-support tool whether or not it is labeled as one.

2. The Conceptual Evolution of Clinical Artificial Intelligence
Understanding what artificial intelligence can and cannot do in clinical settings requires a short
account of how the field arrived at its present shape. The tools now entering practice are the product

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 167
of several distinct technical paradigms, each of which solved certain problems while creating
others, and the limitations of each generation continue to echo in the systems deployed today.

2.1 From rule-based expert systems to learned models
The earliest clinical artificial intelligence took the form of rule-based expert systems: hand-crafted
collections of if-then rules elicited from human specialists and encoded so that a machine could
apply them consistently. These systems were transparent, in that every conclusion could be traced
to an explicit rule, but they were brittle and laborious. The y could not exceed the knowledge
deliberately placed in them, they degraded rapidly outside the narrow domains for which their
rules were written, and maintaining them as medical knowledge changed proved impractical. Their
transparency is nonetheless instructive, because it is precisely the property that later, more capable
systems would sacrifice. Statistical machine learning shifted the source of knowledge from human
elicitation to data. Rather than being told the rules, a model was shown examples and learned the
statistical associations that separated one outcome from another. This made it possibl e to capture
patterns too subtle or too numerous for explicit rules, and it is the foundation of most predictive
and risk-stratification tools in use today. The cost was a loss of transparency and the introduction
of a new dependency: a learned model is only as sound as the data it learned from, and it inherits
the biases, gaps, and idiosyncrasies of that data in ways that are difficult to see.
Deep learning, and in particular the neural networks that process images and other high -
dimensional data, extended this capability dramatically. It is the technology behind the diagnostic
imaging tools that now dominate the regulatory portfolio, because it  excels at exactly the kind of
pattern recognition that medical images demand. Deep models can match or exceed human
performance on well -defined perceptual tasks, but they are also the least interpretable of the
paradigms, the most data-hungry, and the most prone to failing in confident and unexpected ways
when confronted with inputs unlike their training data.
The most recent shift is toward foundation models: very large models trained on vast, general
corpora and then adapted to specific tasks. Large language models are the  most visible example,
and they differ from their predecessors in kind as well as degree. They are general rather than task-
specific, they can be directed with natural language rather than retrained, and they generate content
rather than merely classifying it. This flexibility is the source of both their promise and a new class
of risks, examined in a dedicated section below (Rajpurkar et al., 2022). Table 1 summarizes this
evolution and the governance implications of each transition.

Table 1. Paradigms of clinical artificial intelligence, their representative capabilities,
principal limitations, and governance implications.
Paradigm Representative
capability
Principal limitation Governance
implication
Rule-based expert
systems
Transparent, traceable
inference within a narrow
domain
Brittle; cannot exceed
encoded knowledge;
costly to maintain
Auditable by
construction, but
limited reach
Statistical machine
learning
Risk stratification and
prediction from structured
data
Opaque; inherits data bias
and gaps
Requires data -
provenance and bias
scrutiny

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 168
Paradigm Representative
capability
Principal limitation Governance
implication
Deep learning Human-level perception
on images and signals
Data-hungry; fails
confidently out of
distribution
Demands external
validation and drift
monitoring
Foundation and
generative models
General, language -
directed, content -
generating
Hallucination; unstable
grounding; broad attack
surface
Needs output
verification and use -
case control

2.2 Scope and approach of this review
This review is a narrative synthesis rather than a systematic one. It draws on the peer -reviewed
literature, regulatory documentation, and large real -world evaluations to characterize the state of
clinical artificial intelligence as of 2025, with emphasis on applications that have reached
deployment rather than those confined to deve lopment datasets. It privileges evidence from
prospective and randomized studies where these exist, notes where the evidence base rests on
weaker foundations, and treats the sociotechnical context of deployment as integral to the
assessment rather than ext ernal to it. The organizing thread throughout is the force -multiplier
framing: each capability, risk, and implementation challenge is examined for how it bears on the
combined performance of clinician and machine, which is the unit that ultimately determin es
patient benefit.

3. Advances in Clinical Decision Making
The strongest evidence for artificial intelligence as a clinical force multiplier comes from domains
where the input is structured, the target is well defined, and the cost of a missed or delayed decision
is high. Several such domains illustrate the patter n: diagnostic imaging, the special case of
autonomous diagnosis, early detection of clinical deterioration, and medication safety.

3.1 Diagnostic imaging and pattern recognition
Medical imaging has been the natural first home of clinical artificial intelligence. Images are high-
dimensional, richly structured, and available in volume, and the interpretive task is one where
trained pattern recognition excels. The regulatory record r eflects this conce ntration: radiology
accounts for the largest single share of authorized artificial intelligence enabled devices, and
imaging tools have been among the first to incorporate the lifecycle mechanisms, such as
predetermined change control plans, that anticipate iterative model updates (Ahmed et al., 2025).
The practical value of these tools is best understood through the force -multiplier lens. Most
authorized imaging systems do not read a study and issue a diagnosis; they flag suspicious
findings, triage worklists so that time-critical cases surface first, or measure and quantify features
that a human would otherwise estimate by eye. In this configuration the algorithm does not replace
the radiologist but reallocates the radiologist's attention, concentrating scarce expert time where it
changes outcomes. The evidence base, however, is uneven. A substantial fraction of authorized
imaging tools reached market on the strength of retrospective validation, and independent analyses
have found that clinical validation studies are frequently absent or limited in scope (Chouffani El
Fassi et al., 2024). The lesson is not that imaging artificial intelligence lacks value but that its value
is conditional on validation in the setting where it is deployed.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 169
3.2 Autonomous versus assistive diagnosis
Almost all deployed clinical artificial intelligence is assistive: it informs a human decision rather
than making one. A small but important class of systems is autonomous, producing a clinical
determination without a clinician in the loop, and the contrast between the two illuminates what
the field can and cannot yet responsibly delegate. The canonical example of autonomous diagnosis
is a system for detecting diabetic retinopathy in primary care, evaluated in a prospec tive pivotal
trial that enrolled 900 participants and compared the system against a rigorous reading -center
reference standard. The system produced a diagnostic result in the large majority of patients and
reached a sensitivity of roughly 87 percent and a specificity of roughly 91 percent for more-than-
mild disease, performance sufficient for it to become one of the first autonomous diagnostic
systems authorized for marketing (Abramoff et al., 2018).
Several features of that success are worth drawing out, because they define the narrow conditions
under which autonomy is currently defensible. The task was tightly bounded, the input was a
standardized image, the reference standard was unambiguous, and, c ritically, the system was
locked before the trial so that  it behaved predictably rather than continuing to learn on the job.
Autonomy was granted not because the technology was generally trustworthy but because this
particular task was constrained enough to make trust auditable. The value proposition was also a
force-multiplier one: by enabling screening at the point of primary care, the system extended
access to a specialist assessment that many patients would otherwise never receive. The example
marks the frontier of responsible autonomy rather than a general template, and the overwhelming
majority of clinical artificial intelligence remains, appropriately, assistive.

3.3 Early warning and prediction of deterioration
If imaging is where artificial intelligence sees, prediction is where it anticipates. Early -warning
models aim to detect patients on a trajectory toward deterioration before that trajectory becomes
clinically obvious, buying time for intervention. The same anticipatory logic has been extended
beyond acute deterioration to the early detection of non-communicable and chronic disease, where
AI-driven screening systems aim to identify at -risk individuals earlier than routine care would
(Afrihyia et al., 2023). Sepsis has become the paradigmatic test case, because it is common, lethal,
time-sensitive, and notoriously difficult to recognize early with conventional criteria.
The accumulated evidence here is now substantial enough to support meta-analysis. Synthesizing
dozens of studies and nearly a hundred distinct predictive models, pooled discriminative
performance for artificial intelligence-based sepsis prediction reaches an area under the receiver
operating characteristic curve of roughly 0.87, a level that meaningfully exceeds traditional
bedside scoring in most comparisons (Kim et al., 2026). A broader scoping review spanning
several years of literature reports discriminative performance ranging widely across tools and
settings, with the best -validated systems combining clinical and biomarker data to deliver
actionable, real-time alerts (Rahman et al., 2 025). Structured integration frameworks that embed
prediction within defined critical-care workflows have been associated with reductions in mortality
and length of stay and with improved bundle compliance in modeled and multi -site evaluations
(Salih et al ., 2025).  Two cautions temper this promise. First, discriminative performance in a
development cohort routinely degrades when a model meets a new population, a new
documentation pattern, or a new care process, so headline metrics should be read as ceilings rather
than expectations. Second, and more consequentially, prediction only creates value if it changes
action. A model that fires accurately but into a workflow with no reliable, prespecified response
produces alerts rather than outcomes, and can activel y harm by adding noise. The recurring

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 170
recommendation across the sepsis literature is therefore to shift the evaluative emphasis away from
raw model performance and toward reproducible clinical pathways with predefined use cases and
response protocols (Kim et al., 2026).

3.4 Medication safety and decision support at the point of order
Medication-related decision support is one of the oldest applications of computerized clinical
assistance and one of the most instructive about the limits of naive automation. Conventional
systems generate alerts when an order matches a rule, and the predi ctable consequence has been
alert fatigue: clinicians override the large majority of alerts, including clinically important ones,
because most are irrelevant to the patient in front of them. Artificial intelligence enters here not to
generate more alerts but to make alerts smarter, using patient context to suppress the irrelevant and
surface the consequential (Poly et al., 2024).  This is a subtle but important reframing of what a
force multiplier does. In imaging and early warning, artificial intelligence extends human
perception and anticipation. In medication safety, its most valuable contribution may be
subtractive: removing low-value interruptions so that the alerts that rema in are trusted and acted
upon. The scoping evidence suggests that context -aware models can meaningfully reduce alert
volume while preserving or improving the capture of genuine hazards, though this literature
remains earlier in its maturity than imaging or sepsis prediction, and the same validation cautions
apply.

4. Generative Artificial Intelligence and Large Language Models in Clinical Practice
The arrival of capable large language models has been the defining development of the field in the
period this review covers, and it introduces a category of tool that behaves unlike anything that
preceded it. Where earlier systems classified or predicted,  these models generate: they produce
fluent text, summarize documents, answer questions, and draft clinical content. Their generality is
genuinely new, and so are their failure modes.

4.1 Clinical knowledge, reasoning, and their limits
Large language models have demonstrated a surprising capacity to encode and deploy clinical
knowledge. Purpose -adapted models have performed at or near passing thresholds on medical
licensing-style examinations and have generated answers to clinical questi ons that expert
reviewers rated favorably, prompting serious discussion of their potential in decision support,
triage, and education (Thirunavukarasu et al., 2023; Singhal et al., 2023). This performance is real
and should not be dismissed, but it is easily misread. Performance on structured examinations
measures the retrieval and application of codified knowledge under idealized conditions; it does
not measure reliability in the messy, underspecified, high-stakes reality of clinical care, where the
cost of a confident error is borne by a patient. The central limitation is that these models generate
plausible text rather than verified truth. They can produce fluent, authoritative-sounding statements
that are simply wrong, a failure mode commonly termed hallucination, and they do so without any
signal that would let an unwary reader distinguish the fabricated from the sound. In a clinic al
context this is not a marginal flaw but a defining constraint, because the very fluency that makes
the output useful also makes its errors persuasive. The appropriate posture is therefore verification:
output from a generative model is a draft to be checked by a competent human, never a conclusion
to be trusted on its face.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 171
4.2 The foundations problem and clinical data
A further caution concerns the foundations on which these models rest when applied to clinical
data specifically. Analyses of foundation models built on or applied to electronic health records
have argued that their apparent strength can rest on shaky grou nd: health -record data are
fragmented, inconsistent, and shaped by the idiosyncrasies of billing and documentation rather
than by clinica l truth, and a model that learns from such data may encode artifacts rather than
physiology (Wornow et al., 2023). The implication is that impressive general performance does
not transfer automatically to a specific institution's data, and that local evalu ation is if anything
more essential for generative tools than for their narrower predecessors, precisely because their
generality invites uncritical reuse.

4.3 Patient-facing communication and its double edge
One of the most studied early applications is patient -facing communication. In a widely noted
comparison, responses generated by a language model to patient questions posted in a public forum
were rated by clinicians as higher in both quality and empathy than physician responses to the
same questions (Ayers et al., 2023). The finding is striking and points to a real opportunity: models
may help address the crushing volume of patient messages that contributes to clinician burnout,
and may do so while communicating warmly. The double edge is equally real. A tool that is fluent
and empathetic but occasionally wrong, deployed in a channel where patients may act on its output
without a clinician's review, concentrates exactly the risk that the verification posture is meant to
guard against. The opportunity and the hazard are the same property viewed from two sides, which
is characteristic of generative artificial intelligence in medicine.

4.4 Toward safer generative design
If hallucination is the defining hazard of generative models, then the design patterns that constrain
it are the corresponding priority. Several are emerging. Grounding a model's output in retrieved,
verifiable source documents, rather than relying on the associations encoded in its parameters,
allows a generated statement to be traced to a citable reference and checked. Restricting a model
to bounded, well -specified tasks, such as summarizing a document the clinician can see, rather
than open-ended clinical reasoning, keeps its output within a range where errors are catchable .
Presenting output as an explicitly provisional draft, with the model's uncertainty surfaced rather
than hidden behind fluent prose, supports the verification the clinician is expected to perform. And
confining deployment to workflows where a competent hu man necessarily reviews the output
before it affects a patient preserves the safety margin that the technology's own reliability cannot
yet guarantee. None of these patterns eliminates the underlying limitation, but together they
convert a general-purpose and occasionally unreliable technology into a set of specific tools whose
failure modes are contained by design rather than by hope. The design of the surrounding system,
once again, does more to determine safety than the raw capability of the model.

5. Multimodal Artificial Intelligence and Precision Medicine
Most clinical artificial intelligence to date has operated on a single kind of input: an image, a
stream of vital signs, a set of laboratory values. Clinicians, by contrast, integrate across all of these
at once, and the frontier of the field lies in models that do the same. Multimodal systems combine
imaging, structured electronic -record data, laboratory results, waveforms, and increasingly
genomic and other omic data into a single predictive or diagnostic assessment, aiming to capture
the joint information that any single modality misses.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 172
The rationale is that disease expresses itself across modalities, and that fusing them can yield
assessments more accurate and more individualized than any single st ream allows. Systematic
reviews of multimodal machine learning in precision health describe rapid growth and genuine
promise, particularly where the fusion of medical imaging with electronic -record data allows a
model to condition its reading of an image on the patient's history rather than treating the image in
isolation (Kline et al., 2022; Huang et al., 2020). This is the technical substrate of precision
medicine: the tailoring of prediction and treatment to the individual rather than the population
average. The challenges scale with the ambition. Multimodal models compound the data -quality
and bias problems of each constituent modality, they demand data infrastructure and
interoperability that many institutions lack, and their added complexity deepens the opa city that
already troubles single-modality systems. The evidence base remains earlier in its maturity than
for imaging or documentation, and much of it is still developmental rather than deployed. The
direction of travel is nonetheless clear, and multimodal integration is likely to define the next phase
of clinical artificial intelligence, extending the force -multiplier logic from single tasks to the
integrative reasoning that has historically been the clinician's distinctive contribution.

6. Advances in Health System Efficiency
The efficiency case for clinical artificial intelligence has, somewhat unexpectedly, produced its
most consistent and best-evidenced wins not in the clinical reasoning that captures headlines but
in the administrative work that surrounds it. The clearest example is ambient documentation.

6.1 Ambient documentation and the recovery of clinician time
Ambient artificial intelligence scribes listen to the clinical encounter and generate a draft note,
returning to the clinician a document to review and sign rather than one to compose from scratch.
The appeal is direct: documentation is among the largest and most resented consumers of clinician
time, a major contributor to after -hours work and burnout, and a task where generative languag e
models are genuinely capable.  The evidence has moved quickly from enthusiasm to rigor. A
pragmatic randomized clinical trial across multiple specialties compared two ambient scribe
products against usual care and measured documentation time and validated  burnout instruments
as endpoints, providing the kind of controlled evidence that most clinical artificial intelligence still
lacks (Lukac et al., 2025). Large multi -system quality -improvement evaluations reinforce the
direction of effect: across six health systems, clinicians reported reduced burnout, lower cognitive
task load, and greater ability to remain present with patients after adopting an ambient scribe
(Duggan et al., 2025). A single large integrated system reported that thousands of physicians using
ambient tools across millions of encounters recovered documentation hours equivalent to hundreds
of full workdays, with large majorities reporting improved communication and work satisfaction
(Tierney et al., 2024). A separate pragmatic trial found a clinically meaningful reduction in burnout
scores and roughly half an hour of documentation time saved per provider per day, sufficient to
justify system-wide rollout (Micek et al., 2025).  Ambient documentation is instructive precisely
because it is not a d iagnostic tool, and yet it demonstrates every principle that governs clinical
artificial intelligence. Its benefit is real and measurable, but it depends on the clinician remaining
an active editor rather than a passive approver. Analyses of how clinicians modify ambient drafts
show systematic editing of the model's language, including its expressions of diagnostic
uncertainty, which is both reassuring, because oversight is occurring, and cautionary, because a
tool that quietly shapes the hedging and framing of a clinical note is influencing the record in ways
that are easy to overlook. The efficiency tool is, on inspection, a decision -adjacent tool, and

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 173
because it is built on a generative language model it carries the verification burden described in
the preceding section.

6.2 Operational flow, capacity, and resource allocation
Beyond documentation, artificial intelligence is increasingly applied to the logistics of care:
predicting admission and discharge volumes, forecasting emergency department demand,
optimizing operating-room and bed utilization, and smoothing the scheduling  frictions that leave
expensive capacity idle. Real-time, machine-learning driven risk dashboards embedded in hospital
operations illustrate how continuously updated prediction can surface bottlenecks and resource
risks before they disrupt care (Filani et al., 2022). These applications rarely touch a diagnosis, but
they determine whether the right patient reaches the right resource at the right time, and their
aggregate effect on cost and access can rival that of clinical tools. The mechanism is again
multiplicative: a fixed stock of beds, staff, and theaters yields more care when allocation is better
anticipated. The evidence base for operational applications is more fragmented than fo r
documentation, in part because outcomes are institution -specific and rarely subjected to
randomized evaluation, and in part because operational models are frequently built and deployed
locally rather than authorized as devices. This creates a governance blind spot, discussed below:
high-impact algorithms that shape access to care often sit outside the regulatory perimeter that
governs diagnostic tools, and are correspondingly less scrutinized for bias and drift.

7. Economic, Workforce, and Access Dimensions
The case for clinical artificial intelligence is ultimately made in three currencies: better outcomes,
lower cost, and wider access. Each deserves scrutiny, because the enthusiasm surrounding the
technology often runs ahead of the evidence that it delivers on any of them at system scale.

7.1 Cost, value, and the return on investment
The economic argument for these tools is intuitive but frequently unproven. A model that recovers
clinician time, shortens length of stay, or averts an avoidable complication plausibly pays for itself,
and the ambient-documentation evidence, where recovered hours can be counted directly, comes
closest to a demonstrated return. For most clinical tools, however, the full cost is easy to
underestimate. The purchase price of a mod el is only the beginning; the substantial costs lie in
integration, validation, monitoring, staff training, and the workflow redesign without which even
an accurate tool yield nothing. A rigorous economic assessment must weigh these total costs
against outcomes that are often diffuse and delayed, and the literature that does so remains thin.
The honest position is that the value proposition is strong in a few well -studied applications and
largely presumed in the rest.

7.2 Workforce augmentation rather than replacement
The workforce framing returns the discussion to the force -multiplier thesis. The most defensible
role for these tools is to augment a strained workforce, extending its reach rather than substituting
for it. The convergence of human and machine capability, in which the pairing outperforms either
alone, is a more accurate and more useful model than replacement (Topol, 2019). This framing
also clarifies where value is likely to be found: in relieving the documentation and cognitive
burdens that drive attrition, in extending scarce specialist expertise to settings that lack it, and in
freeing clinician attention for the relational and judgment-intensive work that machines cannot do.
Fears of wholesale replacement are, on current evidence, misplaced;  the realistic and pressing

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 174
question is how to redesign work so that the augmentation is real rather than an added layer of
oversight burden.

7.3 Access, global health, and the equity stakes
The access dimension is where the technology's promise and its peril are both sharpest. In
principle, a model that encodes specialist judgment can carry that judgment to places that have no
specialist, and the autonomous retinopathy -screening example shows this potential concretely: it
extends a specialist assessment in to primary care and, by design, toward populations that would
otherwise go unscreened. Comparative work on the deployment of artificial intelligence in
healthcare across high-income and lower-resource settings, however, cautions that the capabilities
and readiness required to realize this promise are unevenly distributed, and that organizational and
infrastructural gaps can leave the very settings that would benefit most least able to adopt the
technology safely (Afrihyia et al., 2025; Afrihyia et al., 2024 a). Without deliberate attention, a
technology capable of narrowing gaps in access may instead widen them, benefiting well -
resourced systems first and fastest. The equity stakes, developed further in the discussion of bias
below, are therefore not a side i ssue but a central determinant of whether artificial intelligence
multiplies the force of good care or the force of existing disparity.

8. Risks and Failure Modes
Every capability described above carries a corresponding risk, and the risks are not incidental
blemishes on otherwise sound tools but structural features of how machine -learned systems
behave. Six categories deserve particular attention: bias and inequity , brittleness under change,
failure at the human interface, exposure of data and systems, opacity and accountability, and
unresolved liability.

8.1 Algorithmic bias and the amplification of inequity
The most consequential risk is that artificial intelligence, deployed at scale, will encode and
magnify existing inequities. The canonical demonstration remains an analysis of a widely used
commercial risk -prediction algorithm affecting millions of patient s, which was found to
systematically underestimate the health needs of Black patients because it used historical health -
care costs as a proxy for health need; because less had historically been spent on Black patients at
equivalent levels of illness, the a lgorithm inferred that they were healthier, and the effect was to
more than halve the number of Black patients identified for additional care (Obermeyer et al.,
2019). The mechanism is general and easy to overlook: a model trained to predict a convenient but
mismeasured proxy will faithfully reproduce the bias embedded in that proxy, and will do so
invisibly, at a scale and consistency no individual clinician could match.
This risk is compounded by the composition of training data. Models developed on popul ations
that underrepresent particular groups may perform worse for those groups, and the reporting
practices that would reveal such gaps remain inconsistent: subgroup performance and demographic
composition of training data are frequently absent from devic e documentation (Muralidharan et
al., 2024). A tool can thus be both authorized and biased, and the bias can be undetectable to the
clinician using it. The force-multiplier framing cuts both ways here: the same property that lets a
good model extend expert  judgment across a population lets a biased model propagate inequity
across that same population.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 175
8.2 Brittleness, drift, and distribution shift
Machine-learned models encode the statistical structure of the data on which they were trained,
and they degrade when that structure changes. Distribution shift takes many forms: a new patient
population, a change in documentation habits, a new laboratory assay, a different scanner, or a
shift in clinical practice that alters the meaning of the model's inputs. Perf ormance can decay
silently, without any error message, because the model continues to produce confident outputs that
are simply less accurate than they were. Adaptive models that learn continuously introduce the
mirror-image risk that updates may improve a verage performance while degrading it for a
subgroup or introducing new failure modes. This is precisely the concern that lifecycle regulatory
mechanisms attempt to address, and it is the reason that deployment without ongoing monitoring
is not a defensible practice.

8.3 Automation bias, alert fatigue, and the human interface
The point at which a model meets a human is where much of the realized risk lives. Two opposing
failure modes coexist. Automation bias is the tendency to over -trust a machine recommendation,
deferring to it even when independent judgment or available evidence should override it; the more
accurate a tool usually is, the stronger this pull becomes, and the more dangerous its occasional
errors. Alert fatigue is the opposite failure: when a system generates too many low-value outputs,
clinicians learn to dismiss them wholesale, and genuine warnings are lost in the noise. Both failures
share a root cause, which is a mismatch between the model's output and the cognitive and workflow
context of the person receiving it. A clinically accurate model can produce worse outcomes than
no model at all if it is presented in a way that induces either reflexive deference or reflexive
dismissal. This is why the interface and the surrounding workflow are not  cosmetic details but
determinants of safety.

8.4 Privacy, security, and the expanding attack surface
Clinical artificial intelligence concentrates sensitive data and creates new dependencies, and both
expand the attack surface of the health system. Models are trained on large volumes of identifiable
patient data, raising questions about consent, secondary  use, and the possibility that information
about individuals can be recovered from a deployed model. Systems that depend on external
services introduce av ailability risk, where an outage degrades care, and integrity risk, where a
compromised model or data pipeline produces subtly wrong outputs. Comparative work on
privacy-preserving health data governance highlights architectural responses to this exposure,
including cryptographic and distributed -ledger strategies intended to reconcile data utility with
confidentiality, while noting that their maturity and adoption differ sharply across health systems
(Afrihyia et al., 2024b). Regulatory attention to cybersecurity in device documentation has grown
but remains incomplete, and the governance of data flows in artificial intelligence enabled care is
still maturing (Ahmed et al., 2025).

8.5 Opacity, explainability, and accountability
The most capable clinical mode ls are the least interpretable, and this opacity carries practical
consequences beyond intellectual discomfort. When a model cannot explain why it reached a
conclusion, a clinician cannot readily judge whether to trust it in a particular case, a patient cannot
meaningfully contest a decision that affected them, and an institution cannot easily diagnose why
a tool failed when it did. Explainability techniques that attempt to render a model's reasoning
legible are an active area of work, but they are imperfec t and can themselves mislead, offering a

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 176
plausible-seeming account of a decision that does not faithfully reflect how the decision was
actually made. The accountability question is sharper still: when a clinician acting on a model's
output and the model itself jointly produce a harm, responsibility is genuinely difficult to allocate,
and the comfortable assumption that the human always bears it sits uneasily with the reality of
automation bias. Opacity, in short, is not merely a technical property but a gov ernance problem,
because so many of the mechanisms of trust, contestation, and accountability presuppose an
explanation that these systems cannot fully provide.

8.6 Liability and the medicolegal frame
The legal frameworks that govern medical error were not designed for decisions shared between a
clinician and an algorithm, and the resulting uncertainty is itself a risk. When a tool contributes to
a harm, liability may attach to the clinician who relied on it, the institution that deployed it, or the
manufacturer that produced it, and the boundaries between these are unsettled. This uncertainty
shapes behavior in ways that can undermine safety: clinicians may over-rely on an authorized tool
in the belief that doing so is legally safer, or may distrust a useful tool for fear of being blamed for
its errors, and institutions may hesitate to deploy beneficial tools or to withdraw failing ones. A
stable medicolegal frame, in which the responsibilities of each party are clear and the standard of
care in an artificia l intelligence assisted decision is defined, is a precondition for safe adoption
rather than a matter to be settled after the fact. Its absence is a live constraint on the field as of
2025.

9. Evaluation, Validation, and Reporting Standards
If the recurring weakness of clinical artificial intelligence is the gap between reported performance
and demonstrated benefit, then the standards that govern how these tools are evaluated and
reported are not a bureaucratic afterthought but a central leve r for closing that gap. The field has
responded to its own evidentiary problems with a set of reporting guidelines tailored to the specific
ways that artificial intelligence studies can mislead.

9.1 The evidence hierarchy and the retrospective trap
Much of the evidence supporting clinical artificial intelligence sits low on the hierarchy of clinical
evidence. A model that discriminates well on a retrospective dataset has cleared the lowest bar; it
has not shown that it improves decisions, that it works in a new setting, or that it changes outcomes.
External validation, in which a model is tested on data from institutions and populations it was not
trained on, is the minimum needed to establish that performance is not an artifact of the
development data, and prospective evaluation, in which the tool is used in live care and its effect
on decisions and outcomes is measured, is the standard that genuinely matters. The paucity of
prospective and randomized evidence is the field's central evidentiary weakness, and it is why the
randomized trials now emerging for ambient documentation are significant beyond their specific
findings: they model the standard the rest of the field should meet.

9.2 Reporting guidelines specific to artificial intelligence
Recognizing that general trial-reporting standards do not capture the distinctive sources of bias in
artificial intelligence studies, the research community has developed a family of extensions. For
clinical trials of artificial intelligence interventions, the CONSORT -AI extension speci fies
additional reporting items, including clear description of the intervention, the setting of its
integration, the handling of inputs and outputs, the nature of the human -artificial intelligence

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 177
interaction, and an analysis of error cases (Liu et al., 2 020). Its companion for trial protocols,
SPIRIT-AI, applies the same discipline at the design stage (Cruz Rivera et al., 2020). For the
earlier, small-scale clinical evaluation of decision -support systems in live settings, the DECIDE -
AI guideline focuses on the evaluation stage and on systems that support rather than replace human
judgment, addressing the methodological challenges that arise when supported decisions actually
affect care (Vasey et al., 2022). Together these standards, along with related guid ance for
prediction models and diagnostic-accuracy studies, form an emerging scaffold for evidence that is
both more complete and more comparable across studies.
The existence of these standards does not guarantee their use, and adoption remains partial. But
they matter for a structural reason: they encode, as reporting requirements, exactly the questions
that determine whether a tool will help or harm in practice, including where it was validated, how
it interacts with the clinician, and how it fails. A field that reports to these standards is a field that
is forced to confront the sociotechnical realities that this review argues are decisive, and their
diffusion is among the more tractable levers available for raising the dependability of clinical
artificial intelligence.

9.3 External validation and the generalization gap
Underlying the reporting standards is a technical fact that deserves emphasis in its own right: a
model's performance is a property of the pairing of that model with a particular data distribution,
not an intrinsic and portable attribute. A tool that achieves excellent discrimination on the data of
the institution that built it may perform substantially worse elsewhere, because differences in
patient mix, equipment, documentation practice, and care processes shift the very distribution the
model learned. This generalization gap is the reason external validation is not an optional
refinement but a minimum requirement, and it is the reason a favorable headline metric from a
single center should be treated with caution until the tool has been tested against data it did not see
during development. The gap has a practical corollary that bears directly on deployment. Because
performance does not transfer automatically, the institution adopting a to ol cannot rely solely on
the evidence the manufacturer presents; it must, wherever feasible, confirm that the tool performs
adequately on its own population before trusting it, and must continue to confirm this as its
population changes. This is a demanding requirement, and it is one that many institutions are not
yet equipped to meet, which is precisely why the organizational capabilities discussed under
implementation are decisive. The generalization gap converts what might look like a one -time
procurement decision into an ongoing commitment to local evidence, and treating it as anything
less is a common and consequential error.

10. The Regulatory and Governance Landscape
The regulatory response to clinical artificial intelligence has evolved from treating  software as a
static product toward governing it as a lifecycle. The traditional paradigm, in which a device is
evaluated once at market entry, fits poorly with systems designed to learn and change. The central
regulatory innovation of recent years is the  predetermined change control plan, finalized as
guidance in the United States at the end of 2024, which allows a manufacturer to specify in advance
the modifications an algorithm may undergo and the validation and monitoring that will govern
them, permitt ing iterative improvement without a full resubmission for each change (Berkley
Lifesciences, 2025). Complementary guidance has pushed toward greater transparency,
recommending that documentation disclose when a device uses artificial intelligence, describe its
inputs and outputs and performance, and identify known sources of bias (Bipartisan Policy Center,

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 178
2025). These are meaningful steps, but two gaps persist. The first is the evidence gap already
noted: the dominant pathway to market demonstrates substantial equivalence to a predicate rather
than new clinical benefit, and adoption of transparency and lifecycle mechanisms, while growing,
remains a minority of authorizations (Ahmed et al., 2025). The second is a coverage gap. Many
high-impact algorithms, pa rticularly the operational and population -management tools that
allocate resources and shape access, fall outside the device framework entirely, either because they
make no explicit diagnostic claim or because they are built and used internally. The algorithm that
most affected patients in the canonical bias study was of exactly this kind: consequential, widely
used, and effectively ungoverned by device regulation. Closing this gap is less a matter of writing
new rules than of extending existing principles of validation, monitoring, and equity assessment
to the full population of clinically consequential algorithms, wherever they sit.
Internationally, the direction of travel is convergent even where the instruments differ.
Frameworks that classify artificial intelligence enabled medical software as high-risk and demand
data governance, transparency, bias mitigation, and meaningful human oversight are moving
toward force, and coordination among regulators on lifecycle principles has begun. Comparativ e
analyses of AI-driven healthcare governance nonetheless show that executive oversight, regulatory
structure, and accountability differ markedly between high-income and developing health systems,
which shapes how consistently these principles are enforced  in practice (Afrihyia et al., 2024a).
The practical implication for health systems is that governance cannot be outsourced to regulators
alone. Because so much depends on local validation, monitoring, and workflow, the institution
deploying a tool bears i rreducible responsibility for its safe and equitable use, whatever its
regulatory status.

11. Implementation as the Binding Constraint
The recurring theme of this review is that the value of a clinical artificial intelligence tool is
determined less by its performance in isolation than by the quality of the sociotechnical system
into which it is placed. Implementation is where most of the potential value is realized or lost, and
it is the domain where the field is least mature.

11.1 From model performance to clinical pathway
The most important implementation principle is that a prediction is not an intervention. A model
that identifies deteriorating patients accurately produces benefit only when its output is connected
to a reliable, prespecified response: who is notified, wha t they are expected to do, and how the
loop is closed. Where this connection is missing, even an excellent model degenerates into an alert
stream. The literature's shift toward embedding models at defined decision points, with predefined
use cases and response protocols, reflects hard experience that the pathway, not the model, is the
unit that must be designed and evaluated (Kim et al., 2026).

11.2 Workflow integration and cognitive load
A tool that adds work fails regardless of its accuracy. The success of ambient documentation is, in
large part, a success of workflow fit: it removes a burden rather than adding one, and it returns its
output at the natural point in the encounter where a note is needed. Conversely, tools that require
clinicians to leave their normal workflow, reconcile conflicting information, or absorb additional
interruptions face steep adoption barriers even when their underlying models are sound. Designing
for cognitive load, and measuring it as an explicit outcome, is  therefore not a usability nicety but
a determinant of whether a tool helps or harms.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 179
11.3 Trust, oversight, and the preservation of human agency
Sustainable adoption depends on calibrated trust: clinicians must trust a tool enough to use it and
distrust it enough to catch its errors. This calibration is fragile and easily broken in either direction,
and it cannot be assumed. It is built through transparency about what a tool does and does not do,
through visible performance monitoring, and through interfac e design that invites rather than
discourages independent judgment. Evidence from telehealth and remote -monitoring settings
indicates that user trust is tightly coupled to privacy protection and transparent regulatory
governance, so that trust cannot be cu ltivated in isolation from these assurances (Akintola et al.,
2025). Crucially, meaningful human oversight must be preserved in substance and not merely in
form. A clinician who rubber -stamps model output is providing the appearance of oversight
without it s reality, and the ambient -scribe experience, where drafts are systematically edited,
shows both that genuine oversight is achievable and that it must be actively supported rather than
presumed.

11.4 Monitoring, maintenance, and organizational readiness
Deployment is the beginning of a tool's life, not its end. Because models drift and populations
change, a deployed tool requires ongoing surveillance of its performance, including its
performance across subgroups, and a defined process for recalibration, update, or retirement when
performance decays. This demands organizational capabilities that many institutions lack: data
infrastructure, informatics expertise, governance committees empowered to act, and the
willingness to withdraw a tool that is failing. Th e institutions that extract dependable value from
clinical artificial intelligence are distinguished less by the sophistication of their models than by
the maturity of these surrounding capabilities. Assessments of organizational readiness for
artificial i ntelligence adoption reinforce this point, finding that management and operational
capacity, rather than model performance, separates systems able to integrate the technology
dependably, and that such readiness varies widely across settings (Afrihyia et al., 2025).

12. Synthesis: Matching Capability, Risk, and Readiness
The applications surveyed here differ markedly in the strength of their evidence, the concentration
of their risks, and the organizational readiness required to deploy them safely. Table 2 summarizes
this landscape across the major application areas, and the pattern it reveals is consistent: the
domains with the strongest evidence are also those where ground truth is clearest and workflow fit
is best understood, while the domains of greatest potential leverage, particularly operational and
population-management tools, are frequently those with the least external scrutiny.

Table 2. Application areas of clinical artificial intelligence by evidence maturity, principal
risks, and implementation demands.
Application area Evidence maturity
(2025)
Principal risks Key implementation
demand
Diagnostic imaging
triage
Moderate to strong; large
device portfolio, but
many cleared on
retrospective data
Missed or false findings;
automation bias; uneven
subgroup validation
Local validation;
radiologist workflow
integration

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 180
Application area Evidence maturity
(2025)
Principal risks Key implementation
demand
Autonomous
diagnosis (narrow
tasks)
Strong in bounded tasks
with prospective trials;
rare overall
Unaccountable error
without a clinician; scope
creep beyond validated
use
Strict use -case limits;
locked models; access
framing
Deterioration and
sepsis prediction
Strong discriminative
evidence (pooled
AUROC near 0.87);
limited prospective
outcome data
Performance decay
under shift; alert fatigue;
no benefit without a
response pathway
Prespecified response
protocols; embedding at
decision points
Generative tools and
language models
Rapidly growing; strong
on benchmarks, thin on
outcomes
Hallucination;
persuasive error;
unstable grounding on
record data
Human verification;
bounded, checkable use
cases
Ambient
documentation
Strong; randomized and
multi-system real -world
evidence
Silent shaping of the
record; passive approval
replacing oversight
Active clinician editing;
note-quality monitoring
Operational and
capacity optimization
Fragmented; largely
local, rarely randomized
Inequity in access; drift;
governance blind spot
outside device oversight
Internal governance;
bias and drift
surveillance
Population risk
stratification
Widely deployed;
canonical bias failure
documented
Proxy-driven bias
amplified at scale; often
ungoverned by device
rules
Equity audit; correct
target definition;
monitoring
Read together, the rows of Table 2 support the review's central claim. Evidence maturity tracks
not the difficulty of the c linical problem but the clarity of the target and the tractability of the
workflow, and risk concentrates wherever scrutiny is weakest. The applications that most need
governance, the operational and population tools that quietly allocate care, are frequen tly those
that receive the least, because they escape the device framework that disciplines diagnostic tools.
This is the practical frontier for the field: not building more capable models, which is proceeding
rapidly on its own, but extending validation, monitoring, and equity assessment to the full range
of algorithms that now shape care.

13. Future Directions
Several priorities follow directly from the analysis. The first is a decisive shift in the evidentiary
standard from discriminative performance tow ard demonstrated clinical benefit, measured
prospectively and, where feasible, in randomized designs of the kind that ambient documentation
has begun to produce, and reported to the artificial intelligence specific standards now available.
Marketing authorization should be understood as a floor, not a warrant of benefit, and the burden
of demonstrating that a tool helps in a specific setting should rest with the deploying institution as
much as the manufacturer.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 181
The second is the routinization of equity assessment. Subgroup performance and the demographic
composition of training data should be standard, disclosed elements of any clinically consequential
model, and monitoring for disparate performance should be continuous rather than a one -time
exercise. The proxy -driven bias mechanism that produced the canonical failure is general, and
guarding against it requires disciplined attention to what a model is actually trained to predict, not
merely how accurately it predicts it. The third is the maturation of monitoring as a discipline. The
field needs standard, low-friction methods for detecting performance decay and drift in deployed
models, ideally continuous and automated, so that silent degradation becomes visible before it
harms patients. This is th e natural complement to lifecycle regulation: the regulatory framework
anticipates change, but only local monitoring can detect it.
The fourth is the responsible integration of generative and multimodal models. These are the most
capable and the most hazar dous tools the field has produced, and their generality invites exactly
the uncritical reuse that their failure modes punish. Progress here means building the verification,
grounding, and use-case discipline that lets their capability be harnessed without exposing patients
to their confident errors, and resisting the temptation to deploy them beyond the narrow tasks
where their reliability has been established.  The fifth is the extension of governance to the
algorithms that currently escape it. The operatio nal and population -management tools that fall
outside the device perimeter are precisely those with the greatest capacity to shape access to care
at scale, and their exclusion from systematic oversight is the field's most important governance
gap. Closing it does not require novel principles, only the consistent application of existing ones.
Finally, the human interface deserves the same rigor as the model. Automation bias and alert
fatigue are not marginal usability problems but primary determinants of whether a tool is safe, and
the design of the interface, the calibration of trust, and the preservation of substantive human
oversight should be evaluated as carefully as discriminative performance. A stable medicolegal
frame that clarifies responsibility in artificial intelligence assisted decisions is a further
precondition for safe adoption. The most capable model in the world produces no benefit, and can
produce harm, if the person receiving its output cannot use it well.

14. Conclusion
Artificial intelligence has established itself as a genuine force multiplier in health care, and the
framing is apt in both its promise and its warning. Where the target is clear and the workflow is
well understood, in imaging triage, in the early detectio n of deterioration,  and above all in the
recovery of clinician time through ambient documentation, the technology extends the reach and
consistency of expert judgment in ways that are increasingly well evidenced. These are real gains,
achieved against a backdrop of workforce  strain and administrative burden that makes them not
merely convenient but necessary. The arrival of generative and multimodal models widens the
horizon further, promising integrative capabilities that approach the clinician's own, while
introducing failure modes that demand a corresponding discipline of verification.
The same multiplicative property that makes these tools valuable makes their failures
consequential. A biased model does not err once; it errs consistently, across a population, invisibly.
A brittle model degrades silently. A fluent generative model errs p ersuasively. A tool at a poorly
designed interface induces either reflexive deference or reflexive dismissal. The risks are
structural, not incidental, and they cannot be engineered away at the level of the model alone.
The unifying lesson is that the value of clinical artificial intelligence is a property of the system,
not the algorithm. Accuracy is necessary but never sufficient; what determines whether a tool helps
or harms is the quality of the governance, validation, workflow integration, monitoring, and human

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 182
oversight that surround it. The reporting standards and regulatory frameworks have begun to
reflect this understanding, moving from static approval toward lifecycle governance and t oward
evidence that captures the realities of deployment, but a durable gap remains between authorization
and benefit, and an even larger one between the tools that are scrutinized and the tools that most
shape care. The task ahead is therefore less a technical one than an organizational and institutional
one: to build the sociotechnical systems in which a powerful and imperfect technology can
dependably and equitably multiply the force of human expertise, rather than the force of human
error.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 183
References
Abramoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018). Pivotal trial of an
autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary
care offices. npj Digital Medicine, 1, 39.
Afrihyia, E., Akinse, S. G., & Ojukwu, P. U. (2023). Development and implementation of an AI -
driven early detection system for non -communicable diseases. International Journal of
Advanced Multidisciplinary Research and Studies, 3(6), 2680 to 2691.
Afrihyia, E., Akinse, S. G., & Ojukwu, P. U. (2024a). Comparative governance of AI -driven
healthcare management: Executive oversight, regulatory structures, and accountability in
the United States and developing countries. International Journal of Advanced
Multidisciplinary Research and Studies, 4(6), 3087 to 3102.
Afrihyia, E., Ojukwu, P. U., & Akinse, S. G. (2024b). Privacy-preserving health data governance
models: A comparative review of blockchain and cryptographic strategies in U.S. and
developing healthcare systems. International Journal of Advanced Multidisciplinary
Research and Studies, 4(6), 3071 to 3086.
Afrihyia, E., Akinse, S. G., & Ojukwu, P. U. (2025). Organizational readiness for generative AI
integration in healthcare operations: Comparative management capabilities between the
U.S. and low - and middle-income countries. Iconic Research and Engineering Journals,
8(10), 1673 to 1697.
Ahmed, M. I., Spooner, B., Isherwood, J., Lane, M., Orrock, E., & Dennison, A. (2025). Machine
learning-enabled medical devices authorized by the US Food and Drug Administration in
2024: Regulatory characteristics, predicate lineage, and transparency reporting. Journal of
Medical Devices and Regulation, 12(4), 210 to 224.
Akintola, A. S., Fawehinmi, Y. O., Aiyenitaju, O., Chinemerem, B., & Emmanuella, O. ( 2025).
Digital transformation in telehealth: A systematic review of user trust, privacy, and
regulatory governance in AI -powered remote monitoring systems. Journal of Scientific
Research and Reports, 31(11), 163 to 182.
Ayers, J. W., Poliak, A., Dredze, M., Leas, E. C., Zhu, Z., Kelley, J. B., ... & Smith, D. M. (2023).
Comparing physician and artificial intelligence chatbot responses to patient questions
posted to a public social media forum. JAMA Internal Medicine, 183(6), 589 to 596.
Berkley Lifesciences. (2025). The FDA AI/ML SaMD framework: What companies need to know
now. Berkley Life Sciences Regulatory Insights.
Bipartisan Policy Center. (2025). FDA oversight: Understanding the regulation of health AI tools.
Bipartisan Policy Center Issue Brief.
Chouffani El Fassi, S., Abdullah, A., Fang, Y., Kamireddy, S., Casey, J. A., Kabak, A., ... &
Tarran, R. (2024). Not all AI health tools with regulatory authorization are clinically
validated. Nature Medicine, 30(10), 2718 to 2720.
Cruz Rivera, S., Liu, X., Ch an, A. W., Denniston, A. K., & Calvert, M. J. (2020). Guidelines for
clinical trial protocols for interventions involving artificial intelligence: The SPIRIT -AI
extension. Nature Medicine, 26(9), 1351 to 1363.
Duggan, M. J., Gervase, J., Schoenbaum, A., Hanson, W., Chin, S., Kelly, C., ... & Mattison, M.
L. P. (2025). Clinician experiences with ambient scribe technology to assist with
documentation burden and efficiency. JAMA Network Open, 8(2), e2460637.
Filani, O. M., Nnabueze, S. B., Ike, P. N., & Wedraogo, L. (2022). Real -time risk assessment
dashboards using machine learning in hospital supply chain management systems.
International Journal of Multidisciplinary Evolutionary Research, 3(1), 65 to 76.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 184
Huang, S. C., Pareek, A., Seyyedi, S., Banerjee, I., & Lungren, M. P. (2020). Fusion of medical
imaging and electronic health records using deep learning: A systematic review and
implementation guidelines. npj Digital Medicine, 3, 136.
Kim, J., Park, S., Lee, H., & Choi, Y. (2026). Evaluating artificial intelligence for sepsis prediction
in emergency departments: A systematic review and meta -analysis. Journal of Medical
Systems, 50(1), 14 to 33.
Kline, A., Wang, H., Li, Y., Dennis, S., Hutch, M., Xu, Z., ... & Luo, Y. (2022). Multimodal
machine learning in precision health: A scoping review. npj Digital Medicine, 5, 171.
Liu, X., Cruz Rivera, S., Moher, D., Calvert, M. J., & Denniston, A. K. (2020). Reporting
guidelines for clinical trial reports for interventions involving artifici al intelligence: The
CONSORT-AI extension. Nature Medicine, 26(9), 1364 to 1374.
Lukac, P. J., Turner, W., Vangala, S., Chin, A. T., Khalili, J., Shih, Y. T., ... & Mafi, J. N. (2025).
Ambient AI scribes in clinical practice: A randomized trial. NEJM AI, 2(12), 1 to 12.
Micek, M., Tuan, W. J., Bortsov, A., Christensen, J., Arndt, B., & Sinsky, C. (2025). A pragmatic
randomized trial of an ambient artificial intelligence scribe system on clinician burnout and
documentation. Journal of General Internal Medicine, 40(9), 1980 to 1989.
Muralidharan, V., Adewale, B. A., Huang, C. J., Nta, M. T., Ademiju, P. O., Pathmarajah, P., ...
& Oriji, C. (2024). A scoping review of reporting gaps in FDA -approved AI medical
devices. npj Digital Medicine, 7, 273.
Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an
algorithm used to manage the health of populations. Science, 366(6464), 447 to 453.
Poly, T. N., Islam, M. M., Yang, H. C., Nguyen, P. A., Wu, C. C., & Li, Y. C. (2024). The use of
artificial intelligence to optimize medication alerts generated by clinical decision support
systems: A scoping review. Journal of the American Medical Informatics Association,
31(6), 1409 to 1421.
Rahman, A., Iqbal, S., Ahmed, F., & Karim, R. (2025). Bug wars: Artificial intelligence strikes
back in sepsis management. Antibiotics, 14(6), 588 to 611.
Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022). AI in health and medicine. Nature
Medicine, 28(1), 31 to 38.
Salih, S. M., Hassan, T. A., Mohammed, A. K., & Rashid, H. N. (2025). Healthcare 5.0 -driven
clinical intelligence: The learn -predict-monitor-detect-correct framework for systematic
artificial intelligence integration in critical care. Journal of Personalized Medicine, 15(8),
342 to 366.
Singhal, K., Azizi, S., Tu, T., Mahdavi, S. S., Wei, J., Chung, H. W., ... & Natarajan, V. (2023).
Large language models encode clinical knowledge. Nature, 620(7972), 172 to 180.
Thirunavukarasu, A. J., Ting, D. S. J., Elangovan, K., Gutierrez, L., Tan,  T. F., & Ting, D. S. W.
(2023). Large language models in medicine. Nature Medicine, 29(8), 1930 to 1940.
Tierney, A. A., Gayre, G., Hoberman, B., Mattern, B., Ballesca, M., Kipnis, P., ... & Lee, C. (2024).
Ambient artificial intelligence scribes to alleviate the burden of clinical documentation.
NEJM Catalyst Innovations in Care Delivery, 5(3), 1 to 15.
Topol, E. J. (2019). High -performance medicine: The convergence of human and artificial
intelligence. Nature Medicine, 25(1), 44 to 56.
Vasey, B., Nagendr an, M., Campbell, B., Clifton, D. A., Collins, G. S., Denaxas, S., ... &
McCulloch, P. (2022). Reporting guideline for the early -stage clinical evaluation of
decision support systems driven by artificial intelligence: DECIDE -AI. Nature Medicine,
28(5), 924 to 933.

International Journal of Medical Evaluation and Physical Report E -ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No.7 2025 www.iiardjournals.org Online version

IIARD – International Institute of Academic Research and Development

Page 185
Wornow, M., Xu, Y., Thapa, R., Patel, B., Steinberg, E., Fleming, S., ... & Shah, N. H. (2023).
The shaky foundations of large language models and foundation models for electronic
health records. npj Digital Medicine, 6, 135.
